MTH-68/H oncolytic viral treatment in human high-grade gliomas

L. K. Csatary, G. Gosztonyi, J. Szeberényi, Z. Fabian, V. Liszka, B. Bodey, C. M. Csatary

Research output: Contribution to journalArticle

123 Citations (Scopus)

Abstract

Application of virus therapy to treat human neoplasms has over a three decade history. MTH-68/H, a live attenuated oncolytic viral strain of the Newcastle disease virus, is one of the viruses used in the treatment of different malignancies. Here we report on the administration of MTH-68/H to patients with glioblastoma multiforme, the most common and most aggressive neuroectodermal neoplasm with a poor prognosis, averaging six months to a year. Four cases of advanced high-grade glioma were treated with MTH-68/H after the conventional modalities of anti-neoplastic therapies had failed. This treatment resulted in survival rates of 5-9 years, with each patient still living today. Against all odds, each patient resumed a lifestyle that resembles their previous daily routines and enjoys a good quality of life. Each of these patients has regularly received MTH-68/H as their sole form of onco-therapy for a number of years now without interruption.

Original languageEnglish
Pages (from-to)83-93
Number of pages11
JournalJournal of Neuro-Oncology
Volume67
Issue number1-2
DOIs
Publication statusPublished - Mar 2004

Fingerprint

Glioma
Viruses
Therapeutics
Newcastle disease virus
Neoplasms
Glioblastoma
Life Style
Survival Rate
History
Quality of Life
Newcastle disease virus vaccine MTH-68-H

Keywords

  • Apoptosis
  • Chemotherapy
  • Glioblastoma multiforme (GBM)
  • High-grade glioma
  • MTH-68/H
  • Newcastle disease virus (NDV)
  • Programmed cell death (PCD)
  • Virus therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Csatary, L. K., Gosztonyi, G., Szeberényi, J., Fabian, Z., Liszka, V., Bodey, B., & Csatary, C. M. (2004). MTH-68/H oncolytic viral treatment in human high-grade gliomas. Journal of Neuro-Oncology, 67(1-2), 83-93. https://doi.org/10.1023/B:NEON.0000021735.85511.05

MTH-68/H oncolytic viral treatment in human high-grade gliomas. / Csatary, L. K.; Gosztonyi, G.; Szeberényi, J.; Fabian, Z.; Liszka, V.; Bodey, B.; Csatary, C. M.

In: Journal of Neuro-Oncology, Vol. 67, No. 1-2, 03.2004, p. 83-93.

Research output: Contribution to journalArticle

Csatary, LK, Gosztonyi, G, Szeberényi, J, Fabian, Z, Liszka, V, Bodey, B & Csatary, CM 2004, 'MTH-68/H oncolytic viral treatment in human high-grade gliomas', Journal of Neuro-Oncology, vol. 67, no. 1-2, pp. 83-93. https://doi.org/10.1023/B:NEON.0000021735.85511.05
Csatary, L. K. ; Gosztonyi, G. ; Szeberényi, J. ; Fabian, Z. ; Liszka, V. ; Bodey, B. ; Csatary, C. M. / MTH-68/H oncolytic viral treatment in human high-grade gliomas. In: Journal of Neuro-Oncology. 2004 ; Vol. 67, No. 1-2. pp. 83-93.
@article{b49d66277e0546f48192f974bad1718e,
title = "MTH-68/H oncolytic viral treatment in human high-grade gliomas",
abstract = "Application of virus therapy to treat human neoplasms has over a three decade history. MTH-68/H, a live attenuated oncolytic viral strain of the Newcastle disease virus, is one of the viruses used in the treatment of different malignancies. Here we report on the administration of MTH-68/H to patients with glioblastoma multiforme, the most common and most aggressive neuroectodermal neoplasm with a poor prognosis, averaging six months to a year. Four cases of advanced high-grade glioma were treated with MTH-68/H after the conventional modalities of anti-neoplastic therapies had failed. This treatment resulted in survival rates of 5-9 years, with each patient still living today. Against all odds, each patient resumed a lifestyle that resembles their previous daily routines and enjoys a good quality of life. Each of these patients has regularly received MTH-68/H as their sole form of onco-therapy for a number of years now without interruption.",
keywords = "Apoptosis, Chemotherapy, Glioblastoma multiforme (GBM), High-grade glioma, MTH-68/H, Newcastle disease virus (NDV), Programmed cell death (PCD), Virus therapy",
author = "Csatary, {L. K.} and G. Gosztonyi and J. Szeber{\'e}nyi and Z. Fabian and V. Liszka and B. Bodey and Csatary, {C. M.}",
year = "2004",
month = "3",
doi = "10.1023/B:NEON.0000021735.85511.05",
language = "English",
volume = "67",
pages = "83--93",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1-2",

}

TY - JOUR

T1 - MTH-68/H oncolytic viral treatment in human high-grade gliomas

AU - Csatary, L. K.

AU - Gosztonyi, G.

AU - Szeberényi, J.

AU - Fabian, Z.

AU - Liszka, V.

AU - Bodey, B.

AU - Csatary, C. M.

PY - 2004/3

Y1 - 2004/3

N2 - Application of virus therapy to treat human neoplasms has over a three decade history. MTH-68/H, a live attenuated oncolytic viral strain of the Newcastle disease virus, is one of the viruses used in the treatment of different malignancies. Here we report on the administration of MTH-68/H to patients with glioblastoma multiforme, the most common and most aggressive neuroectodermal neoplasm with a poor prognosis, averaging six months to a year. Four cases of advanced high-grade glioma were treated with MTH-68/H after the conventional modalities of anti-neoplastic therapies had failed. This treatment resulted in survival rates of 5-9 years, with each patient still living today. Against all odds, each patient resumed a lifestyle that resembles their previous daily routines and enjoys a good quality of life. Each of these patients has regularly received MTH-68/H as their sole form of onco-therapy for a number of years now without interruption.

AB - Application of virus therapy to treat human neoplasms has over a three decade history. MTH-68/H, a live attenuated oncolytic viral strain of the Newcastle disease virus, is one of the viruses used in the treatment of different malignancies. Here we report on the administration of MTH-68/H to patients with glioblastoma multiforme, the most common and most aggressive neuroectodermal neoplasm with a poor prognosis, averaging six months to a year. Four cases of advanced high-grade glioma were treated with MTH-68/H after the conventional modalities of anti-neoplastic therapies had failed. This treatment resulted in survival rates of 5-9 years, with each patient still living today. Against all odds, each patient resumed a lifestyle that resembles their previous daily routines and enjoys a good quality of life. Each of these patients has regularly received MTH-68/H as their sole form of onco-therapy for a number of years now without interruption.

KW - Apoptosis

KW - Chemotherapy

KW - Glioblastoma multiforme (GBM)

KW - High-grade glioma

KW - MTH-68/H

KW - Newcastle disease virus (NDV)

KW - Programmed cell death (PCD)

KW - Virus therapy

UR - http://www.scopus.com/inward/record.url?scp=1842484851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842484851&partnerID=8YFLogxK

U2 - 10.1023/B:NEON.0000021735.85511.05

DO - 10.1023/B:NEON.0000021735.85511.05

M3 - Article

C2 - 15072452

AN - SCOPUS:1842484851

VL - 67

SP - 83

EP - 93

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1-2

ER -